{
  "trial_id": "NCT03083808",
  "trial_group": "cancer",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, gender, ECOG Performance Status, histology type, prior treatments, mutation status (EGFR, ALK, ROS1), laboratory values, pregnancy status (for women of childbearing potential), contraception use, time since last PD-1/PD-L1 inhibitor therapy, presence of CNS metastases, history of autoimmune disease, history of pneumonitis, history of immune-related toxicity, infection status, HIV/HBV/HCV status, TB history, hypersensitivity history, vaccination history.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "pregnancy status (for women of childbearing potential)"
        ],
        [
          "Histology",
          "histology type"
        ],
        [
          "Baseline ECOG",
          "ECOG Performance Status"
        ],
        [
          "Prior checkpoints inhibitors (CPI)",
          "prior treatments"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Race (NIH/OMB)",
        "Region of Enrollment",
        "Smoking Status",
        "First-line Chemo"
      ],
      "remaining_candidate_features": [
        "gender",
        "mutation status (EGFR, ALK, ROS1)",
        "laboratory values",
        "contraception use",
        "time since last PD-1/PD-L1 inhibitor therapy",
        "presence of CNS metastases",
        "history of autoimmune disease",
        "history of pneumonitis",
        "history of immune-related toxicity",
        "infection status",
        "HIV/HBV/HCV status",
        "TB history",
        "hypersensitivity history",
        "vaccination history"
      ]
    }
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, ECOG Performance Status, Histology, Smoking Status, Prior Treatment History, PD-1/PD-L1 Inhibitor Response Duration, Laboratory Values (e.g., blood counts, liver function tests), Contraceptive Use,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Histology",
          "Histology"
        ],
        [
          "Baseline ECOG",
          "ECOG Performance Status"
        ],
        [
          "Prior checkpoints inhibitors (CPI)",
          "PD-1/PD-L1 Inhibitor Response Duration"
        ]
      ],
      "remaining_reference_features": [
        "Race (NIH/OMB)",
        "Region of Enrollment",
        "Smoking Status",
        "First-line Chemo"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Smoking Status",
        "Prior Treatment History",
        "Laboratory Values (e.g., blood counts, liver function tests)",
        "Contraceptive Use"
      ]
    }
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, ECOG Performance Status, Histology, Previous platinum-based chemotherapy, Previous PD-1 or PD-L1 inhibitor therapy, Time from last infusion of PD-1 or PD-L1 inhibitor therapy, Best response to previous PD-1 or PD-L1 inhibitor therapy, Progression-free survival on previous PD-1 or PD-L1 inhibitor therapy.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ],
        [
          "Histology",
          "Histology"
        ],
        [
          "Baseline ECOG",
          "ECOG Performance Status"
        ],
        [
          "Prior checkpoints inhibitors (CPI)",
          "Previous PD-1 or PD-L1 inhibitor therapy"
        ],
        [
          "First-line Chemo",
          "Previous platinum-based chemotherapy"
        ]
      ],
      "remaining_reference_features": [
        "Race (NIH/OMB)",
        "Smoking Status"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Time from last infusion of PD-1 or PD-L1 inhibitor therapy",
        "Best response to previous PD-1 or PD-L1 inhibitor therapy",
        "Progression-free survival on previous PD-1 or PD-L1 inhibitor therapy."
      ]
    }
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, ethnicity, ECOG Performance Status, histology, stage of NSCLC, prior therapies, time since last infusion of PD-1 or PD-L1 inhibitor, best response to prior PD-1 or PD-L1 inhibitor, presence of EGFR exon 19 or 21 mutations or ALK or ROS1 gene rearrangements, smoking status.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Race (NIH/OMB)",
          "race"
        ],
        [
          "Histology",
          "histology"
        ],
        [
          "Baseline ECOG",
          "ECOG Performance Status"
        ],
        [
          "Prior checkpoints inhibitors (CPI)",
          "prior therapies"
        ],
        [
          "Smoking Status",
          "smoking status"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Region of Enrollment",
        "First-line Chemo"
      ],
      "remaining_candidate_features": [
        "ethnicity",
        "stage of NSCLC",
        "time since last infusion of PD-1 or PD-L1 inhibitor",
        "best response to prior PD-1 or PD-L1 inhibitor",
        "presence of EGFR exon 19 or 21 mutations or ALK or ROS1 gene rearrangements"
      ]
    }
  }
}